Audrey Sternberg | Authors


Risk Factors Linked to Discontinuation of Adjuvant Abemaciclib in HR+/HER– Breast Cancer

June 06, 2022

Several key risk factors seen in the monarchE trial of adjuvant abemaciclib could help early monitoring of patients with hormone receptor–positive, HER2-negative, node-positive high-risk early breast cancer to prevent discontinuation.

Daratumumab and Carfilzomib Quadruplet and Tandem Transplant Appears Feasible for High-Risk Myeloma

June 05, 2022

Based on a 2022 ASCO Annual Meeting presentation given by Cyrille Touzeau, MD, PhD, the IFM 2018-04 study confirms the efficacy and feasibility of the quadruplet induction regimen Dara-KRd in high-risk, transplant-eligible patients with multiple myeloma.

Pembrolizumab With Ramucirumab Boosts Survival Vs SOC in ICI-Resistant NSCLC

June 03, 2022

The use of pembrolizumab plus ramucirumab to treat non–small cell lung cancer in immune checkpoint inhibitor resistant patients showed better overall survival versus standard of care regimens in the Lung-MAP nonmatched phase 2 substudy S1800A.